Most patients lose 65–80% of excess weight.

MagDI uses magnets to create a duodeno-ileal connection without sutures, combined with sleeve gastrectomy for metabolic weight loss.

Call the same day if you cannot keep fluids down for about aday, if vomiting persists or returns after stopping, or if you noticedehydration signs such as dizziness, dark urine, or a racing heart. Seekemergency care immediately for vomiting combined with abdominal pain, fever,and a fast heart rate, or for any confusion, vision changes, or unsteadiness,which can indicate a dangerous thiamine deficiency.

‍

If you have corrected your eating technique and still vomit, a structural or functional problem may be present. After a sleeve, a stricture (narrowing) isthe classic cause and often appears two to six months out. After a bypass, marginal ulcers, a gastrojejunal stricture, or an internal hernia should be considered. In patients with persistent post-bypass vomiting, endoscopy finds a significant abnormality about 62 percent of the time, so evaluation is worthwhile.

TheseGLP-1 medications slow stomach emptying and can leave food in the stomach despite fasting, which raises anesthesia safety concerns. Many teams hold weekly injections for about a week and daily pills on the day of surgery, but recommendations vary and management is individualized. The most important step is to tell your surgical and anesthesia team that you take one and exactly when you took your last dose.

Cravings decrease because satiety hormones — especially GLP‑1 and PYY — surge after surgery. These hormones strengthen fullness signals, reduce reward‑driven eating, and calm the brain pathways that respond to sugar and high‑calorie foods. Patients often say food “feels different” or “doesn’t have the same hold on me.” This is a direct result of gut‑brain hormonal changes, not discipline. Surgery resets the biology that drives cravings.

Metabolism improves within days because surgery rapidly increases insulin sensitivity, stabilizes blood sugar, reduces inflammation, and changes bile acid signaling. These shifts happen before significant weight loss. Patients experience fewer energy crashes, fewer cravings, and better metabolic control almost immediately. This is why bariatric surgery is one of the most effective treatments for type 2 diabetes — it changes metabolic biology, not just calorie intake.

The set‑point is the weight your body biologically defends. In obesity, the set‑point is too high — the body fights weight loss by increasing hunger and slowing metabolism. After bariatric surgery, hormonal and metabolic changes lower the set‑point. Your body begins defending a healthier, lower weight, making weight loss sustainable. Patients stop “fighting their biology” and finally feel like their body is working with them instead of against them.

The post-op bariatric diet is a structured,staged meal progression that every bariatric patient follows after surgery. Itmoves through five stages: clear liquids (days 1 to 3), full liquids (days 4 to7), pureed foods (starting day 8), soft foods (approximately week 3), andregular solids (weeks 4 to 6). Each stage is designed to match the healingtimeline of the surgical anatomy, prevent dehydration, and preserve lean bodymass.

Most patients begin introducing regular solidfood around weeks 4 to 6 after surgery. The progression is gradual: clearliquids (days 1 to 3), full liquids (days 4 to 7), pureed foods (starting day8), soft foods (approximately week 3), and regular solids (weeks 4 to 6).

MagDI is an emerging, largely investigational procedure. The first human cases were performed in late 2021, and current evidence comes from small prospective and multicenter studies with mostly one-year follow-up. Unlike the SADI-S and duodenal switch, it does not yet have established society endorsement or long-term durability data, so availability is limited and often study-based. Discuss current status directly with a bariatric program (Gagner et al., Surgery for Obesity and Related Diseases, 2024).

Three ways. MagDI uses magnets instead of staples or sutures to form the connection; the duodenum is left intact rather than divided; and food flows through two pathways (bipartition) instead of being fully rerouted. About 19% of a meal passes through the new magnetic connection while the rest follows the normal route (Cadiere et al., Journal of Gastrointestinal Surgery, 2024).

The early signal is encouraging. Across the 43-patient multicenter series there were no device-related anastomotic leaks, and a systematic review of magnetic compression anastomosis reported a 0% leak rate and no deaths across 106 patients. The proposed reason is that magnetic compression lets the tissue heal before the channel opens, unlike a stapled connection that is open under pressure immediately. These are early, small-cohort findings, not long-term proof (Gagner et al., Surgery for Obesity and Related Diseases, 2024; Kaur et al., Surgical Endoscopy, 2026).

At one year, MagDI plus a concurrent sleeve produced roughly 34% total weight loss and 80% excess weight loss, comparable to the SADI-S and duodenal switch at that time point. Diabetes improvement has been strong, with HbA1c falling from 8.2% to 6.6% at one year in the first-in-human study and sustained glycemic improvement out to four years with a related magnetic technique. Long-term weight-maintenance data specific to MagDI are not yet available (Gagner et al., Surgical Endoscopy, 2023; Gagner et al., Journal of the American College of Surgeons, 2025; Jirapinyo et al., Obesity Surgery, 2026).

Yes. Because the sleeve is the first component, MagDI can be added as a planned or revisional second stage without redoing the sleeve. Additional weight loss in that setting is more modest, about 8 kg at 6 months, since the original sleeve already produced much of the hormonal effect (Gagner et al., Surgery for Obesity and Related Diseases, 2024).

The 2022 ASMBS/IFSO guidelines recommend metabolic and bariatric surgery for people with a BMI of 35 or higher, regardless of whether they have obesity-related conditions. They also recommend considering surgery for people with a BMI of 30–34.9 who have metabolic disease, particularly when nonsurgical treatment has not led to adequate improvement. Individual evaluation is essential, and guidelines do not guarantee insurance coverage.

Insurance plans set their own coverage policies, which may rely on older criteria or add plan-specific requirements. These can include documentation of supervised weight-management programs or other conditions. Coverage varies by policy, so check your plan’s current requirements and ask your bariatric team about documentation and appeal options.

No. BMI is a measure based on height and weight, but it does not distinguish muscle from fat or show where fat is distributed. Clinicians may consider other health information, such as obesity-related conditions, metabolic markers, and body composition, as part of an evaluation. How those measures affect eligibility and coverage varies

The perioperative (30-day) mortality rate of modern bariatric surgery is approximately 0.03% to 0.2%, pooled at about 0.08% across more than 1.2 million procedures (Jumaev et al., Obesity Surgery, 2025; Arterburn et al., JAMA, 2020). That is comparable to having a knee replacement and about half the risk of gallbladder removal (Böckelman et al., Obesity Surgery, 2017). The risk varies by procedure, with sleeve gastrectomy and gastric bypass among the safest.

For eligible patients, yes. Living with untreated severe obesity carries substantially higher long-term risk than surgery. Bariatric surgery lowers all-cause mortality by 30–50% and is linked to a median life expectancy roughly 6 years longer than usual care, along with large reductions in diabetes, hypertension, and cardiovascular death (Syn et al., Lancet, 2021; Wiggins et al., PLoS Medicine, 2020). The risk of not operating often exceeds the risk of surgery.

Long-term risks include reoperation (about 5–22%, higher after gastric bypass), procedure-specific issues such as marginal ulcers or internal hernia after bypass and reflux after sleeve, nutritional deficiencies requiring lifelong supplements, and mental-health considerations (Arterburn et al., JAMA, 2020; Courcoulas et al., BMJ, 2023). These are real but manageable with lifelong vitamin monitoring and structured multidisciplinary follow-up.

Lorem Ipsum

Can metabolic surgery reverse diabetes?

Most patients return to normal activities within 1–2 weeks.